{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:23Z","timestamp":1793296103662,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["109TMU\\u2011SHH\\u201116"],"award-info":[{"award-number":["109TMU\\u2011SHH\\u201116"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["110TMU\\u2011SHH\\u201106"],"award-info":[{"award-number":["110TMU\\u2011SHH\\u201106"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["111TMU\\u2011SHH\\u201123"],"award-info":[{"award-number":["111TMU\\u2011SHH\\u201123"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC111-2314-B038-146-MY2"],"award-info":[{"award-number":["NSTC111-2314-B038-146-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC113-2314-B038-112-MY3"],"award-info":[{"award-number":["NSTC113-2314-B038-112-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["NSTC113-2314-B038-115"],"award-info":[{"award-number":["NSTC113-2314-B038-115"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejps.2026.107434","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:09:42Z","timestamp":1767859782000},"page":"107434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting PPP1R15B and ATF4 axis in hepatocellular carcinoma: A novel strategy for overcoming lenvatinib-tolerant persister cells through GPX4-mediated ferroptosis induction"],"prefix":"10.1016","volume":"218","author":[{"given":"Ming-Yao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiue-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijesh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iat-Hang","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Tai","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuen-Haur","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4380","authenticated-orcid":false,"given":"Yih-Giun","family":"Cherng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107434_bib0001","doi-asserted-by":"crossref","unstructured":"Chidambaranathan-Reghupaty S., Fisher P.B., Sarkar D.: Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv. Cancer Res. 2021, 149:1\u201361.","DOI":"10.1016\/bs.acr.2020.10.001"},{"issue":"22","key":"10.1016\/j.ejps.2026.107434_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225844","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: from epidemiology to diagnostic approach","volume":"13","author":"Grgurevic","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ejps.2026.107434_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejps.2026.107434_bib0004","doi-asserted-by":"crossref","unstructured":"hepatology EAFTSOTLJJo: EASL clinical practice guidelines: management of hepatocellular carcinoma. 2018, 69(1):182\u2013236.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"10.1016\/j.ejps.2026.107434_bib0005","doi-asserted-by":"crossref","unstructured":"Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.-.F., De Oliveira A.C., Santoro A., Raoul J.-.L., Forner AJNEjom: Sorafenib in advanced hepatocellular carcinoma. 2008, 359(4):378\u2013390.","DOI":"10.1056\/NEJMoa0708857"},{"key":"10.1016\/j.ejps.2026.107434_bib0006","doi-asserted-by":"crossref","unstructured":"Yamamoto Y., Matsui J., Matsushima T., Obaishi H., Miyazaki K., Nakamura K., Tohyama O., Semba T., Yamaguchi A., Hoshi SSJVc: Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. 2014, 6(1):1\u201313.","DOI":"10.1186\/2045-824X-6-18"},{"key":"10.1016\/j.ejps.2026.107434_bib0007","doi-asserted-by":"crossref","unstructured":"Fu R., Jiang S., Li J., Chen H., Zhang X.J.M.O.: Activation of the HGF\/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. 2020, 37(4):1\u20137.","DOI":"10.1007\/s12032-020-01350-4"},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ejps.2026.107434_bib0009","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/JTO.0b013e31829f691f","article-title":"High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?","volume":"8","author":"Ye","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107434_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.07.002","article-title":"Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure","volume":"32","author":"Guler","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0011","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2026.107434_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ejps.2026.107434_bib0013","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"42","key":"10.1016\/j.ejps.2026.107434_bib0014","doi-asserted-by":"crossref","first-page":"35299","DOI":"10.1074\/jbc.M112.379883","article-title":"A subunit of eukaryotic translation initiation factor 2\u03b1-phosphatase (CreP\/PPP1R15B) regulates membrane traffic","volume":"287","author":"Kloft","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/ijms19010127","article-title":"Differential characterization of temozolomide-resistant Human glioma cells","volume":"19","author":"Lai","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2026.107434_bib0016","doi-asserted-by":"crossref","unstructured":"Rojas M., Vasconcelos G., Dever T.E.: An eIF2\u03b1-binding motif in protein phosphatase 1 subunit GADD34 and its viral orthologs is required to promote dephosphorylation of eIF2\u03b1. 2015, 112(27):E3466\u2013E3475.","DOI":"10.1073\/pnas.1501557112"},{"issue":"5","key":"10.1016\/j.ejps.2026.107434_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.06.030","article-title":"Target-based discovery of an inhibitor of the regulatory phosphatase PPP1R15B","volume":"174","author":"Krzyzosiak","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2026.107434_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1370012","article-title":"Activating transcription factor 4: a regulator of stress response in human cancers","volume":"12","author":"Wu","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"24","key":"10.1016\/j.ejps.2026.107434_bib0019","first-page":"8592","article-title":"Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines","volume":"63","author":"Tanabe","year":"2003","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejps.2026.107434_bib0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.03.016","article-title":"ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis","volume":"79","author":"He","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40164-023-00427-w","article-title":"Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy","volume":"12","author":"Zheng","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"1\u20133","key":"10.1016\/j.ejps.2026.107434_bib0022","first-page":"40","article-title":"Novel insights on ferroptosis modulation as potential strategy for cancer treatment: when nature kills","volume":"40","author":"Consoli","year":"2023","journal-title":"Antioxid. Redox Signal."},{"issue":"7","key":"10.1016\/j.ejps.2026.107434_bib0023","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/cas.15378","article-title":"Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma","volume":"113","author":"Iseda","year":"2022","journal-title":"Cancer Sci."},{"issue":"7873","key":"10.1016\/j.ejps.2026.107434_bib0024","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2026.107434_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107163","article-title":"Pharmacological agents targeting drug-tolerant persister cells in cancer","volume":"203","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"31","key":"10.1016\/j.ejps.2026.107434_bib0026","article-title":"EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"issue":"7","key":"10.1016\/j.ejps.2026.107434_bib0027","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.ymthe.2021.03.022","article-title":"Emerging mechanisms and targeted therapy of ferroptosis in cancer","volume":"29","author":"Wang","year":"2021","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1016\/j.ejps.2026.107434_bib0028","first-page":"1182","article-title":"Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells","volume":"10","author":"Ye","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0029","first-page":"323","article-title":"Erastin\/sorafenib induces cisplatin\u2011resistant non\u2011small cell lung cancer cell ferroptosis through inhibition of the Nrf2\/xCT pathway","volume":"19","author":"Li","year":"2020","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.ejps.2026.107434_bib0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.28574","article-title":"Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis","volume":"64","author":"Sun","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0031","article-title":"Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.ejps.2026.107434_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122601","article-title":"Tolerant\/persister cancer cells and the path to resistance to targeted therapy","volume":"9","author":"Swayden","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejps.2026.107434_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102908","article-title":"Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: a systematic review","volume":"135","author":"Galli","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.ejps.2026.107434_bib0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.livres.2024.05.004","article-title":"Hepatitis B virus as a risk factor for hepatocellular carcinoma: there is still much work to do","volume":"8","author":"Abdelhamed","year":"2024","journal-title":"Liver Res."},{"issue":"4","key":"10.1016\/j.ejps.2026.107434_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.ejps.2026.107434_bib0037","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/cam4.5224","article-title":"Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: chemotherapy versus multikinase inhibitors","volume":"12","author":"Oranratnachai","year":"2023","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.ejps.2026.107434_bib0038","doi-asserted-by":"crossref","first-page":"779","DOI":"10.21037\/hbsn-22-322","article-title":"Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future","volume":"11","author":"Sarkar","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.ejps.2026.107434_bib0039","first-page":"187","article-title":"Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, pdgfr\u03b1, KIT and RET","volume":"211","author":"Zsch\u00e4bitz","year":"2018","journal-title":"Recent Results in Cancer Research Fortschritte der Krebsforschung Progres Dans Les Recherches Sur Le Cancer"},{"issue":"20","key":"10.1016\/j.ejps.2026.107434_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205097","article-title":"Dose consideration of Lenvatinib's anti-cancer effect on hepatocellular carcinoma and the potential benefit of combined colchicine therapy","volume":"15","author":"Lin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejps.2026.107434_bib0041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12876-025-03861-8","article-title":"Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Gastroenterol."},{"issue":"7382","key":"10.1016\/j.ejps.2026.107434_bib0042","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejps.2026.107434_bib0043","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res."},{"issue":"7533","key":"10.1016\/j.ejps.2026.107434_bib0044","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejps.2026.107434_bib0045","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","article-title":"Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex","volume":"7","author":"Zawistowski","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ejps.2026.107434_bib0046","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ejps.2026.107434_bib0047","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ejps.2026.107434_bib0048","doi-asserted-by":"crossref","unstructured":"Harding H.P., Zhang Y., Scheuner D., Chen J.-.J., Kaufman R.J., Ron DJPotnaos: Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2\u03b1) dephosphorylation in mammalian development. 2009, 106(6):1832\u20131837.","DOI":"10.1073\/pnas.0809632106"},{"key":"10.1016\/j.ejps.2026.107434_bib0049","doi-asserted-by":"crossref","unstructured":"Shi W., Sun C., He B., Xiong W., Shi X., Yao D., Cao XJTJocb: GADD34\u2013PP1c recruited by Smad7 dephosphorylates TGF\u03b2 type I receptor. 2004, 164(2):291\u2013300.","DOI":"10.1083\/jcb.200307151"},{"key":"10.1016\/j.ejps.2026.107434_bib0050","doi-asserted-by":"crossref","unstructured":"Li H.-.Y., Liu H., Wang C.-.H., Zhang J.-.Y., Man J.-.H., Gao Y.-.F., Zhang P.-.J., Li W.-.H., Zhao J., Pan XJNi: Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. 2008, 9(5):533\u2013541.","DOI":"10.1038\/ni.1600"},{"issue":"33","key":"10.1016\/j.ejps.2026.107434_bib0051","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1038\/sj.onc.1210289","article-title":"Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines","volume":"26","author":"Igarashi","year":"2007","journal-title":"Oncogene"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:26:36Z","timestamp":1773984396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"alternative-id":["S0928098726000084"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107434","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PPP1R15B and ATF4 axis in hepatocellular carcinoma: A novel strategy for overcoming lenvatinib-tolerant persister cells through GPX4-mediated ferroptosis induction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107434"}}